Mouzin Douglas E, Lorenzen Marianne J, Haworth John D, King Vickie L
Veterinary Medicine Biologicals Research and Development, Pfizer Animal Health, Pfizer Inc, 7000 Portage Rd, Kalamazoo, MI 49001, USA.
J Am Vet Med Assoc. 2004 Jan 1;224(1):55-60. doi: 10.2460/javma.2004.224.55.
To determine whether vaccinated dogs either remained seropositive or responded serologically to revaccination for 5 key viral antigens after extended periods since their last vaccination.
Serologic survey.
322 healthy client-owned dogs.
Dogs were > or = 2 years old and vaccinated against canine distemper virus (CDV), canine adenovirus-1 (CAV-1), canine adenovirus-2 (CAV-2), canine parainfluenza virus (CPIV), and canine parvovirus (CPV). On day 0, dogs were revaccinated with a vaccine from the same vaccine line as they had historically received. Antibody titers were measured in sera collected at day 0 (prevaccination titer) and 5 to 7 days later (postvaccination titer). Dogs were considered to have responded serologically if they had a day-0 serum neutralization titer to CDV > or = 1:32; a serum neutralization titer to CAV-1, CAV-2, or CPIV > or = 1:16; a hemagglutination inhibition titer to CPV > or = 1:80; or a > or = 4-fold increase in antibody titer after revaccination.
The percentage of dogs that had titers at or greater than the threshold values or responded to revaccination with a > or = 4-fold increase in titer was 98.1% for CDV, 98.4% for CAV-1, 99.0% for CAV-2, 100% for CPIV, and 98.1% for CPV.
In most dogs, vaccination induced a response that lasted up to and beyond 48 months for all 5 antigens. Although not equivalent to challenge-of-immunity studies as a demonstration of efficacy, results suggest that revaccination with the same vaccine provides adequate protection even when given less frequently than the traditional 1-year interval. The study provides valuable information for clinicians to help determine appropriate revaccination intervals.
确定接种疫苗的犬只在最后一次接种疫苗后的较长时间内,对于5种关键病毒抗原是否仍保持血清学阳性或对再次接种产生血清学反应。
血清学调查。
322只健康的客户拥有的犬只。
犬只年龄大于或等于2岁,已接种犬瘟热病毒(CDV)、犬腺病毒1型(CAV-1)、犬腺病毒2型(CAV-2)、犬副流感病毒(CPIV)和犬细小病毒(CPV)疫苗。在第0天,犬只接种与它们以往接种的同一疫苗系列的疫苗。在第0天(接种前滴度)和5至7天后(接种后滴度)采集血清,测量抗体滴度。如果犬只对CDV的第0天血清中和滴度大于或等于1:32;对CAV-1、CAV-2或CPIV的血清中和滴度大于或等于1:16;对CPV的血凝抑制滴度大于或等于1:80;或再次接种后抗体滴度升高大于或等于4倍,则认为其产生了血清学反应。
对于CDV,滴度达到或高于阈值或再次接种后滴度升高大于或等于4倍的犬只百分比为98.1%;CAV-1为98.4%;CAV-2为99.0%;CPIV为100%;CPV为98.1%。
在大多数犬只中,接种疫苗诱导的反应对所有5种抗原持续长达48个月及更久。尽管作为效力证明,这与免疫激发研究不等同,但结果表明,即使接种频率低于传统的1年间隔,使用相同疫苗再次接种仍可提供足够的保护。该研究为临床医生帮助确定合适的再次接种间隔提供了有价值的信息。